Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation
oleh: Ines H. Kaltheuner, Kanchan Anand, Jonas Moecking, Robert Düster, Jinhua Wang, Nathanael S. Gray, Matthias Geyer
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2021-11-01 |
Deskripsi
Abemaciclib is a third generation CDK-directed drug used in the treatment of HR + /HER2 negative advanced or metastatic breast cancer. Here the authors demonstrate that members of the Homeodomain-interacting protein kinases (HIPKs) HIPK3 and DYRK1A are also targeted by Abemaciclib.